ACAD vs CBRE · P/E 15, rev $576.0M vs P/E 43, rev $21.75B
ACADIA Pharmaceuticals Inc (ACAD) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the ACAD and CBRE stock pages for the full models.
Not investment advice.